alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 6-K
 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
  
 JAMES HARDIE INDUSTRIES N.V.
  
 
 þ o
 
 
 
 o þ




---



##### 



TABLE OF CONTENTS
 Safe Harbor Statement
    
    
    3Exhibit Index
    
    
    4Signatures
    
    
    5EXHIBIT 99.1
  2




---



##### Table of Contents



Safe Harbor Statement
  
    
    expectations about the timing and amount of payments to the Asbestos Injuries
Compensation Fund (AICF), a special purpose fund for the compensation of proven
asbestos-related personal injury and death claims;
    
    expectations concerning the costs associated with the suspension of operations at our
Blandon, Pennsylvania and Plant City, Florida plants;
    
    statements as to the possible consequences of proceedings brought against us and
certain of our former directors and officers by the Australian Securities and Investments
Commission;
    
    statements regarding tax liabilities and related proceedings;
    
    expectations that our credit facilities will be extended or renewed;
    
    projections of our operating results or financial condition;
    
    statements regarding our plans, objectives or goals, including those relating to
competition, acquisitions, dispositions and our products;
    
    statements about our future performance; and
    
    statements about product or environmental liabilities.
   3




---



##### Table of Contents



EXHIBIT INDEX
 Exhibit No.
    
    DescriptionExhibit 99.1
    
    Appendix 3B  New issue announcement  Filed with the
Australian Stock Exchange on June 20, 2008
 4




---



##### Table of Contents



SIGNATURES
  James Hardie Industries N.V.Date: June 23, 2008
    By:
    /s/ Russell ChenuRussell ChenuManaging Director 5




---



##### Table of Contents



EXHIBIT INDEX
 Exhibit No.
    
    DescriptionExhibit 99.1
    
    Appendix 3B  New issue announcement  Filed with the
Australian Stock Exchange on June 20, 2008
IN THE SUPREME COURT OF PENNSYLVANIA MIDDLE DISTRICT

**IN RE: APPOINTMENT OF DEPUTY CONSTABLE FOR HIGHSPIRE,**  **PENNSYLVANIA, JOHN FRY**

**PETITION OF: COMMONWEALTH OF PENNSYLVANIA**  **No. 256 MAL 2015**

**Petition for Allowance of Appeal from the Order of the Commonwealth Court** 

ORDER

PER CURIAM

AND NOW **, this 9th day of September, 2015, the Petition for Allowance of Appeal** 

**is** DENIED

**.**
**EXHIBIT32.1**

 

*CHIEF EXECUTIVE OFFICERCERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350*

 

In connection withthe Quarterly Report of MedicalCV, Inc. (the “Company”) on Form 10-QSB/A forthe quarter ended July 31, 2003, as filed with the Securities and ExchangeCommission on the date hereof (the “Report”), I, Blair P. Mowery, President andChief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,that:

 

1.                                       theReport fully complies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

2.                                       theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 

A signed originalof this written statement required by Section 906 has been provided to theCompany and will be retained by the Company and furnished to the Securities andExchange Commission or its staff upon request.

 

 
| Dated: March 22, 2004 | By:                                   | /s/ Blair P. Mowery |   |
|-----------------------|---------------------------------------|---------------------|--------|
|                  | Blair P. Mowery                       |
|                  | President and Chief Executive Officer |

 

1

----
SPECIAL POWER OF ATTORNEY

         The  undersigned  constitutes  and  appoints  Jon Ehlinger his true and
lawful   attorney-in-fact   and  agent  with  full  power  of  substitution  and
resubstitution,  for him  and in his  name,  place,  and  stead,  in any and all
capacities,  to sign the Annual  Report on Form 10-K for the  fiscal  year ended
December 31, 1999,  for filing with the  Securities  and Exchange  Commission by
Ugly Duckling  Corporation,  a Delaware  corporation,  together with any and all
amendments  to such Form 10-K,  and to file the same with all exhibits  thereto,
and all  documents in connection  therewith,  with the  Securities  and Exchange
Commission,  granting to such  attorneys-in-fact  and agents,  and each of them,
full  power  and  authority  to do and  perform  each and  every  act and  thing
requisite and  necessary to be done in and about the  premises,  as fully and to
all intents and purposes as he might or could do in person, hereby ratifying and
confirming  all that such  attorneys-in-fact  and agents,  or each of them,  may
lawfully do or cause to be done by virtue hereof.

         DATED:   February 15, 2000


          /S/ CHRISTOPHER D. JENNINGS
          -----------------------
          Christopher D. Jennings
Fourth Court of Appeals

San Antonio, Texas

January 6, 2015

No. 04-14-00488-CV

IN THE INTEREST OF T.F., A Child,

From the 288th Judicial District Court, Bexar County, Texas

Trial Court No. 2011-PA-02356

Honorable David A. Canales, Judge Presiding

ORDER

This is an appeal from a judgment terminating appellant mother’s parental rights. 

Appellant’s court-appointed appellate counsel has filed a brief and motion to withdraw pursuant 

to Anders v. California, 386 U.S. 738 (1967), in which he asserts there are no meritorious issues 

to raise on appeal. See In re RR, No. 04-03-00096-CV, 2003 WL 21157944 (Tex. App.—San 

Antonio May 21, 2003, order) (holding that Anders procedures apply to appeals from orders 

terminating parental rights), disp. on merits, 2003 WL 22080522 (Tex. App.—San Antonio Sept. 

10, 2003, no pet.) (mem. op.). Counsel has informed appellant of her right to obtain and review 

the record and file her own brief. See id.; Nichols v. State, 954 S.W.2d 83, 85-86 (Tex. App.—

San Antonio July 23, 1997, no pet.); Bruns v. State, 924 S.W.2d 176, 177 n.1 (Tex. App.—San 

Antonio 1996, no pet.). Counsel provided appellant with a form for requesting the record and 

instruction on filing same. See Kelly v. State, No. PD-0702-13, 2014 WL 2865901 (Tex. Crim. 

App. June 25, 2014). Appellant did not file the form with this court or otherwise request the 

record. 

If appellant desires to file a pro se brief, we order that she do so on or before February

5, 2015. If appellant files a timely pro se brief, appellee may file a responsive brief no later than 

twenty days after appellant’s pro se brief is filed in this court. We further order the motion to 

withdraw filed by appellant’s counsel held in abeyance pending further order of the court.

We further order the clerk of this court to serve a copy of this order on appellant mother, 

appellant father, and all counsel.

_________________________________

Karen Angelini, Justice
IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 6th day of January, 2015.

___________________________________

Keith E. Hottle

Clerk of Court
<PAGE>   1
 
                                                                    EXHIBIT 23.2
 
                        CONSENT OF INDEPENDENT AUDITORS
 
We consent to the references to our firm under the caption "Experts" and to the
use of our report dated March 1, 1996, except for Note 17, as to which the date
is June 12, 1996, in the Registration Statement on Form S-1 and related
Prospectus of IXC Communications, Inc. for the registration of 2,000,000 shares
of common stock.
 
                                          /s/ Ernst & Young LLP
 
                                          --------------------------------------
 
Austin, Texas
January 28, 1997
The Rodenticides NOICA Toxicological OverviewDr. Ray KentHealth Effects DivisionOffice of Pesticide ProgramsOfficeofPesticideProgramsNovember 29, 2011The RMD RodenticidesRodenticide TypeWarfarin1stgenerationanticoagulant‐coumarinWarfaringenerationanticoagulantcoumarinChlorophacinone 1stgenerationanticoagulant‐indandioneDiphacinone 1stgenerationanticoagulant‐indandioneBrodifacoum2ndgenerationanticoagulant‐coumarinBromadiolone 2ndgenerationanticoagulant‐coumarinDifenacoum 2ndgenerationanticoagulant‐coumarinDifethialone2ndgenerationanticoagulant‐coumarinCh l l if lH lidCholecalciferolypercalcemiainducerBromethalinMitochondrialuncouplerZincphosphideMitochondrialuncoupleruncoupler2Acute toxicityAcute oral toxicity categoriesToxicityCategoryOral LD50U d i l di50/kIII> 50 thru 500 mg/kgUp to andincluding50mg/kgIIIIV000 /k> 500 thru 5000 mg/kgg g> 5000mg/kg4Rodenticide acute toxicityRodenticide TypeRatoralLD50(mg/kg)Warfarin1stgen anticoagulant 3Chlorophacinone 1stgenanticoagulant 3.15Diphacinone 1stgenanticoagulant 2.1Brodifacoum2ndgenanticoagulant 0.42B di l2 di l0 56romadiolonendgenantcoaguant.Difenacoum 2ndgenanticoagulant 1.17Difethialone2ndgenanticoagulant0 55anticoagulant.Cholecalciferol Hypercalcemiainducer 42BromethalinMitochondrialuncoupler2 6.Zincphosphide Mitochondrialuncoupler 215The NOIC Rodenticides6Indandione Anticoagulants7Rodenticide Plasma Half-livesBloodRatoralLD50Rodenticideoodhalf‐lifeato a50(mg/kg)Wfi(1t)40h3Warfarin(1stgen)40hours3Brodifacoum(2ndgen)16‐36days0.42Brodifacoum(2Difethialone(2ndgen) no data 0.55Bromethalin 5.6days 2.68The NOIC AnticoagulantsRodenticideTypeWarfarin Coumarinanticoagulant‐1stgenBrodifacoum Coumarinanticoagulant‐2ndgenDifethialone Coumarinanticoagulant‐2ndgen9The Vitamin K CycleAnticoagulantAnticoagulant10Symptoms of AnticoagulantPoisoningEl iI i l tti ti•ary signs–Increasein clottingtime.Not observable in a home setting, butrather in a medical facilityratherinamedicalfacility.•Moderate symptoms - easy bruising andbleeding from almost any tissue such asbleedingfromalmostanytissuesuchasgums, nose, urinary tract, G.I. tract, etc.•Severe symptoms-Massive loss ofSeveresymptomsMassivelossofblood leading potentially to death.11Bromethalin•Mitochondrial uncoupler of oxidativeh h l tiATP lphosphorylation–noongerreplenished by consumption of O2.•Symptoms of bromethalin poisoningoccur within a few hours of ingestion.•There is no antidote similar to vitaminK for bromethalin poisoning.Kforbromethalinpoisoning.12Symptoms of BromethalinPoisoningEl iF t•ary signs–ew symptoms areregarded as “signature” effects. At lowdoses an individual might exhibit mentaldoses,anindividualmightexhibitmentalconfusion or dullness.•Moderate effects-as cerebrospinalModerateeffectsascerebrospinalpressure increases there may beindications of weakness in limb strength•Severe effects - general paralysis orconvulsions andpossiblydeathy13Conclusions•All of the rodenticides are highlytoxic if ingested•A single bite of any of theAsinglebiteofanyoftherodenticides by a child posest bl i kunacceptable risks•Prevention of exposure is thesurest way to avoid risks fromrodenticide ingestionrodenticideingestion14
<PAGE>


                                                                   EXHIBIT 24.1



                               POWER OF ATTORNEY


The undersigned director and/or officer of Karrington Health, Inc. (the
"Company"), does hereby constitute and appoint Richard R. Slager and Thomas
J. Klimback, or either of them, my true and lawful attorneys and agents, each
with full power of substitution, to do any and all acts and things in my name
and on my behalf in my capacity as a director of the Company and to execute
any and all instruments for me and in my name in the capacity indicated
above, which said attorneys or agents, or either of them, may deem necessary
or advisable to enable the Company to comply with the Securities Exchange Act
of 1934, as amended, and any rules, regulations and requirements of the
Securities and Exchange Commission thereunder, in connection with the filing
requirements of the Company's Annual Report on Form 10-K for the fiscal year
ended December 31, 1997 (the "1997 Form 10-K"), including specifically but
without limitation, power and authority to sign for me in my name, in the
capacity indicated above, the 1997 Form 10-K and any and all amendments to
such 1997 Form 10-K; and I do hereby ratify and confirm all that the said
attorneys and agents, or their substitute or substitutes, or either of them,
shall do or cause to be done by virtue hereof.

                                        /s/ RICHARD R. SLAGER
                                        Richard R. Slager
                                        Chairman of the Board and
                                        Chief Executive Officer
<PAGE>

                                                                    EXHIBIT 10.1

                                  AMENDMENT TO

                           SOFTWARE LICENSE AGREEMENT

        AGREEMENT,  made as of September 16, 2003 by and between  3720161 Canada
Corporation,  a Canadian corporation,  d/b/a Mobilair Integration  ("Mobilair");
and Medical Licensing International Corp., a Delaware corporation ("MLSI").

        WHEREAS, the parties have entered into a Software License Agreement (the
"License Agreement") dated the date hereof, which provides,  among other things,
for the  issuance  of  12,900,000  shares  of MLSI  restricted  common  stock to
Mobilair; and

        WHEREAS,  Mobilair has advised MLSI, that in consideration of money owed
by it to Dominion Investments Ltd. ("Dominion") for financial and legal services
rendered,  that 3,870,000 of the 12,900,000  MLSI shares are to be issued in the
name of Dominion and sent directly to Dominion upon issuance.

        NOW IT IS HEREBY AGREED AS FOLLOWS

        1. REMUNERATION. Section 5 of the License Agreement is hereby amended to
read as follows:

        "5. REMUNERATION

                5.1     As a  consideration  to the  granting  of the  exclusive
                        rights  pursuant to Section 2  hereunder,  the  Licensee
                        agrees to allot and issue to Mobilair and its assignees,
                        the following  restricted  shares of common stock of its
                        capital stock (the "Licensee Restricted Shares").

                5.1.1   as of the date of this  Agreement,  Licensee shall issue
                        to  Mobiliar  an   aggregate   of   9,030,000   Licensee
                        Restricted Shares;

                5.1.2   as  of  the  date  of  this  Agreement  and  as  further
                        consideration  for the license,  Licensee shall issue an
                        aggregate of 1,000,000 Licensee Restricted Shares to the
                        Mobilair Employees listed on Schedule 5.1.2 hereto;

                5.1.3   as  of  the  date  of  this  Agreement  and  as  further
                        consideration  for the  license,  Licensee  shall  issue
                        3,870,000   Licensee   Restricted   Shares  to  Dominion
                        Investments Ltd."

        2. NO OTHER  CHANGES.  All other  terms and  provisions  of the  License
Agreement shall continue with full force and effect.


                                       1
<PAGE>



        IN WITNESS  WHEREOF,  the parties  have signed this  Amendment as of the
16th day of September 2003.


3720161 CANADA CORPORATION

By:     /s/ Daniel Veilleux

        Name:  Daniel Veilleux
        Title: President


MEDICAL LICENSING INTERNATIONAL CORP.

By:     /s/ Gilles Cloutier

        Name:  Gilles Cloutier
        Title: President



                                       2
# NOTICE This technical report does not necessarily represent final EPA decisions or positions. It is intended to present technical analysis of issues using data that are currently available. The purpose in the release of such reports is to facilitate the exchange of technical information and to inform the public of technical developments. 

# Assessment and Standards Division Office of Transportation and Air Quality U.S. Environmental Protection Agency National Renewable Energy Laboratory U.S. Department of Energy Coordinating Research Council 

# EPAct/V2/E - 89: Assessing the Effect of Five Gasoline Properties on Exhaust Emissions from Light - Duty Vehicles Certified to Tier 2 Standards Final Report on Program Design and Data Collection Appendix H Fuel Blending Experiment to Characterize Carryover Effects

E PA-420-R-13-004 April 2013

# H-2 Investigation of Fuel Carryover Effects on Distillation Parameters July 27, 2009 Fuel 1 Fuel 2 Fuel 1 Fuel 27 Fuel 1 Fuel 6 Fuel 2 Fuel 21 Fuel 27 Fuel 21 Ethanol Content vol. % 10 0 10 15 10 10 0 20 15 20 T50 oF 150 240 150 220 150 190 240 160 220 160 T90 oF 300 340 300 340 300 340 340 300 340 300 DVPE psi 10.0 10.0 10.0 6.65 10.0 6.65 10.0 6.65 6.65 6.65 Aromatics vol. % 15 15 15 15 15 15 15 40 15 40

EtOH Target Meas. Target Meas. Target Meas. Fuel 1 Fuel 2 10 100 0 10 9.93 150 149.8 300 297.2 0 0 100 10 10.22 240 237.9 340 339 5 95 10.64 236 338.8 95 5 10.05 150.6 301.7
Fuel 1 Fuel 27 10 100 0 10 9.93 150 149.8 300 297.2 15 0 100 6.65 6.87 220 221.7 340 339.3 5 95 7.01 216.1 339.2 95 5 9.81 150.9 301.9
Fuel 1 Fuel 6 10 100 0 10 9.93 150 149.8 300 297.2 10 0 100 6.65 7.21 190 189.4 340 340.3 5 95 7.23 186 339.2 95 5 9.72 150.4 301.7
Fuel 2 Fuel 21 0 100 0 10 10.22 240 237.9 340 339 20 0 100 6.65 6.98 160 168.8 300 304.8 5 95 7.27 169.2 305.9 95 5 10.75 235.8 336.4
Fuel 27 Fuel 21 15 100 0 6.65 6.87 220 221.7 340 339.3 20 0 100 6.65 6.98 160 168.8 300 304.8 5 95 6.95 168.6 305.2 95 5 6.83 217.8 338.9

►F ollow EPAct Fuel Sampling Procedure ►Blend fuels A3, A4, B3, B4, C3, C4, D3, D4, E3 and E4 ►Perform D86 test on the fuels of each set in the course of a single day ▬ Use exclusively OptiDist equipment ▬ Use the same distillation still for all tests Fuel 27: 1/2 gal Fuel Pair E Fuel Pair D Fuel Pair C

21 2 Components Fuel Set C Test Fuel

Fuel Set D

27 

### Scope of Work: PROPERTY UNIT



## Test Fuel Sets Fuel Pair A Fuel Pair B

Fuel 2: 1/2 gal Fuel 6: 1 qt Fuel 21: 1/2 gal E4 E3 21 Test Fuel
B4 B3 27 1

D3

are being tested on that day Components

Fuel Set E Components Test Fuel

► Obtain samples of fuels 1,2,6,21 and 27 Sample sizes (~2X needed volume): Test Fuel

Fuel 1: 1 gal D4 2

► Note: The same fuel need not be tested twice on a given day, if it belongs to two different fuel sets which 6 1 C4 C3 Fuel Set B A3 A4 Components 

## RVP T50 T90 Fuel Set A Test Fuel 1 Components
**Exhibit 32.1**

 

**CERTIFICATIONOF CHIEF EXECUTIVE OFFICER**

**PURSUANTTO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

Theundersigned, S. Bradford Antle, the Chief Executive Officer of SIInternational, Inc. (the “Company”), has executed this certification inconnection with the filing with the Securities and Exchange Commission of theCompany’s Quarterly Report on Form 10-Q for the period ended April 1, 2006 (the“Report”). The undersigned hereby certifies that:

 

(1)           the Report fully complies with therequirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934;and

 

(2)           the information contained in theReport fairly presents, in all material respects, the financial condition andresults of operations of the Company.

 
| May  9, 2006 | SI  INTERNATIONAL, INC.                |
|--------------|----------------------------------------|
|         |                                   |
|         |                                   |
|         | /s/  S. BRADFORD ANTLE                 |
|         | S.  Bradford Antle                     |
|         | President  and Chief Executive Officer |
|              |                                        |  |

 

1

----

 

**CERTIFICATIONOF CHIEF FINANCIAL OFFICER**

**PURSUANTTO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO**

**SECTION906 OF THE SARBANES-OXLEY ACT OF 2002**

 

Theundersigned, Thomas E. Dunn, the Chief Financial Officer of SI International,Inc. (the “Company”), has executed this certification in connection with thefiling with the Securities and Exchange Commission of the Company’s QuarterlyReport on Form 10-Q for the period ended April 1, 2006 (the “Report”). Theundersigned hereby certifies that:

 

(1)           the Report fully complies with therequirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934;and

 

(2)           the information contained in theReport fairly presents, in all material respects, the financial condition andresults of operations of the Company.

 
| May  9, 2006 | SI  INTERNATIONAL, INC.                                           |
|--------------|-------------------------------------------------------------------|
|         |                                                              |
|         |                                                              |
|         | /s/  THOMAS E. DUNN                                               |
|         | Thomas  E. Dunn                                                   |
|         | Executive  Vice President,  Chief Financial Officer and Treasurer |
|              |                                                                   |  |

 

2

----
Exhibit
32.2





Certification
of Principal Financial Officer Regarding Periodic Report Containing Financial
Statements pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002





I, Bruce
W. Elder, the Principal Financial Officer of Crescent Financial Corporation, in
compliance with 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, hereby certify that, (i) the Form 10-Q filed by
Crescent Financial Corporation (the "Issuer") for the quarter ended March 31,
2009, fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, and (ii) the information contained in that
report fairly presents, in all material respects, the financial condition and
results of operations of the Issuer on the dates and for the periods presented
therein.





Date: May 14, 2009
              
              /s/
      Bruce W. ElderBruce
      W. ElderPrincipal
      Financial Officer